DBV Technologies | DBVT - Sales Revenues

Stock Price
21.42
Daily Change
-0.82 -3.67%
Monthly
-12.38%
Yearly
409.88%
Q1 Forecast
20.91

DBV Technologies reported $2.77M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.67M 23.07M Sep/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
BioMarin Pharmaceutical USD 875M 99M Dec/2025
DBV Technologies USD 2.77M 1.31M Sep/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025